ANIP · Ani Pharmaceuticals Inc
$77.61
-0.93 (-1.18%)
At close · Jul 24
Market Cap
$1.77B
Shares
22.75M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$883.37M
+43.8%
FY2025
Net Income
$78.34M
+522.9%
FY2025
Gross Margin
58.19%
-11.2pp
FY2020
Operating Margin
12.58%
+12.5pp
FY2025
Diluted EPS
$3.32
+419.2%
FY2025
Operating Cash Flow
$185.23M
+189.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $923.71M | $883.37MG | $614.38M | $486.82M | $316.39M | $216.14M | $208.48M | $206.55M | $201.58M | $176.84M | $128.62M | $76.32M | $55.97M | $30.08M | $20.37M | $435.16K | $2.47M | $1.26M | |
| — | $13.66M | $12.5M | $16.03M | $8.69M | $461K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $8326 | $12.67K | $11.65K | |
| — | $85.34M | — | — | — | — | — | $87.16M | $63.15M | $73.02M | $79.03M | $48.78M | $12.69M | $11.47M | $9.97M | $9.17M | — | — | — | |
| — | $127.88M | — | — | — | — | — | $121.32M | $143.39M | $128.55M | $97.81M | $79.84M | $63.63M | $44.5M | $20.11M | $11.2M | — | — | — | |
| — | — | — | — | — | — | — | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% | 83.37% | 79.5% | 66.84% | 55% | — | — | — | |
| — | $51.7M | $51.66M | $44.58M | $34.29M | $22.32M | $11.37M | $16M | $19.81M | $15.39M | $9.07M | $2.91M | $2.87M | $2.68M | $1.71M | $1.16M | $44.18M | $39.71M | $13.68M | |
| — | $8.35M | — | — | — | — | — | — | — | — | — | — | — | — | — | $8.23M | $6.98M | $5.94M | $5.37M | |
| — | $314.87M | $317.75M | $249.64M | $161.7M | $124.04M | $84.29M | $64.99M | $55.84M | $44.06M | $31.58M | $27.83M | $21.16M | $17.94M | $16.39M | $9.52M | — | — | — | |
| — | $80.5M | $82.5M | $60.3M | $52.3M | $49.5M | $41.8M | $39.9M | $40.2M | $31.7M | $26.7M | $21.4M | $6.2M | $3.3M | $600K | $50K | — | — | — | |
| — | $89.45M | $91.42M | $67.73M | $59.79M | $56.97M | $47.25M | $44.64M | $44.61M | $33.74M | $27.93M | $22.34M | $6.9M | $3.88M | $1.11M | $567K | $148.24K | $167.99K | $137.28K | |
| — | $799.92M | $772.27M | $613.79M | $439.85M | $351.67M | $255.93M | $224.49M | $190.2M | $166.22M | $148.51M | $108.54M | $43.62M | $35.96M | $29.18M | $20.41M | $51.36M | $46.08M | $48.68M | |
| — | $123.79M | $111.09M | $584K | $46.97M | -$35.28M | -$39.79M | -$16.02M | $16.35M | $35.36M | $28.33M | $20.08M | $32.7M | $20.01M | $898K | -$42K | — | — | — | |
| — | — | 12.58% | 0.1% | 9.65% | -11.15% | -18.41% | -7.68% | 7.92% | 17.54% | 16.02% | 15.61% | 42.84% | 35.74% | 2.99% | -0.21% | — | — | — | |
| — | $213.23M | $202.51M | $68.32M | $106.76M | $21.69M | $7.46M | $28.62M | $60.96M | $69.1M | $56.26M | $42.42M | $39.6M | $23.88M | $2.01M | $525K | — | — | — | |
| — | $374K | — | — | — | — | — | — | — | — | — | — | — | — | $467K | $1.33M | $681.57K | $688.08K | $147.03K | |
| — | $8407 | — | — | — | — | — | — | — | — | — | — | — | — | — | $8539 | $8326 | $12.67K | $11.65K | |
| — | $1.09M | $1.93M | -$4.03M | -$159K | $670K | -$4.34M | -$494K | -$228K | -$550K | $55K | -$74K | $41K | $160K | -$305K | -$241K | — | — | — | |
| — | $116.03M | $95.79M | -$22.21M | $19.87M | -$62.67M | -$56.06M | -$25.96M | $3.16M | $20.05M | $16.35M | $8.68M | $21.73M | $19.38M | $126K | -$1.61M | -$51.61M | -$46.2M | — | |
| — | $23.88M | $17.45M | -$3.69M | $1.09M | -$14.77M | -$13.46M | -$3.41M | -$2.94M | $4.56M | $17.43M | $4.74M | $6.36M | -$9.37M | $20K | -$36K | $0 | — | — | |
| — | $92.15M | $78.34M | -$18.52M | $18.78M | -$47.9M | -$42.6M | -$22.55M | $6.09M | $15.49M | -$1.08M | $3.93M | $15.38M | $28.75M | $301K | -$1.51M | — | — | — | |
| — | — | 8.87% | -3.01% | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -0.61% | 3.06% | 20.14% | 51.36% | 1% | -7.39% | — | — | — | |
| — | $91.4M | $77.18M | -$20.15M | $17.15M | -$49.52M | -$42.79M | -$22.55M | $6.09M | $15.34M | -$1.08M | $3.91M | $15.29M | $28.59M | -$4.87M | -$8.5M | -$51.61M | -$46.2M | -$47.53M | |
| — | $89.02M | $74.03M | -$22.04M | $15.47M | -$32.67M | -$34.22M | -$29.11M | $1.6M | $15.12M | -$1.08M | $3.93M | — | — | — | — | — | — | — | |
| USD/shares | — | — | $3.50 | -$1.04 | $0.86 | -$3.05 | -$3.40 | -$1.88 | $0.51 | $1.31 | -$0.09 | $0.34 | $1.34 | $2.61 | -$0.92 | -$1.27 | -$3.15 | -$4.21 | -$8.40 |
| USD/shares | $9.19 – $9.69* | — | $3.32G | -$1.04 | $0.85 | -$3.05 | -$3.40 | -$1.88 | $0.50 | $1.30 | -$0.09 | $0.34 | $1.32 | $2.59 | -$0.92 | -$1.27 | -$3.15 | -$4.21 | -$8.40 |
| shares | — | — | 20.05M | 19.32M | 18M | 16.26M | 12.6M | 11.96M | 11.84M | 11.68M | 11.55M | 11.45M | 11.37M | 10.94M | 5071 | 21.76M | 16.4M | 10.99M | 5.66M |
| shares | — | — | 21.23M | 19.32M | 18.19M | 16.26M | 12.6M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M | 11.56M | 11.05M | 5071 | 21.76M | 16.4M | 10.99M | 5.66M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2025: $36.49M in buybacks, $6.22M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.91×
Drug Manufacturers - Specialty & Generic median 2.24×
EV/EBIT
14.22×
Drug Manufacturers - Specialty & Generic median 34.34×
P/E (TTM)
19.86×
Drug Manufacturers - Specialty & Generic median 20.32×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Rare Disease and Brands | $483,933,000 | $294,342,000 | $197,502,000 | $81,148,000 | — | — |
| Generics and Other | $399,433,000 | $320,034,000 | $289,314,000 | $235,237,000 | — | — |
| Generics Established Brands and Other | — | — | — | — | $216,136,000 | $208,475,000 |
| Rare Disease | — | — | — | — | $0 | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $852,443,000 | $604,989,000 | $486,251,000 | $312,427,000 | $211,893,000 | $202,881,000 | $199,663,000 | $196,886,000 |
| Non Us | $30,923,000 | $9,387,000 | $565,000 | $3,958,000 | — | — | — | — |
| Canada | — | — | — | — | $4,243,000 | $5,594,000 | $6,884,000 | $4,690,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total Sales of Rare Disease and Brands | $483,954,000 | $294,342,000 | $197,501,000 | $81,148,000 | — | — | — | — |
| Total Sales of Rare Disease Pharmaceutical Products | $422,646,000 | $229,599,000 | $112,117,000 | $41,686,000 | — | — | — | — |
| Total Sales of Generics and Other | $399,412,000 | $320,034,000 | $289,315,000 | $235,237,000 | — | — | — | — |
| Sales of Generic Pharmaceutical Products | $384,110,000 | $301,004,000 | $269,449,000 | $210,120,000 | $143,571,000 | $147,257,000 | $128,729,000 | $117,451,000 |
| Sales of Cortrophin Gel | $347,778,000 | $198,085,000 | $112,117,000 | $41,686,000 | — | — | — | — |
| Sales of ILUVIEN and YUTIQ | $74,868,000 | $31,514,000 | $0 | $0 | — | — | — | — |
| Sales of Established Brands | $61,308,000 | $64,743,000 | $85,384,000 | $39,462,000 | — | — | — | — |
| Unapproved Products | $24,100,000 | $22,400,000 | $22,400,000 | $14,200,000 | $16,200,000 | $16,900,000 | $20,700,000 | $24,900,000 |
| Sales of Royalties and Other Pharmaceutical Services | $15,302,000 | $19,030,000 | $19,866,000 | $25,117,000 | — | — | — | — |
| Other Revenues | — | — | — | $693,000 | $1,857,000 | $783,000 | $980,000 | $929,000 |
| Product Development Services | — | — | — | $2,949,000 | $1,310,000 | $1,858,000 | $1,125,000 | $1,019,000 |
| Royalties From Licensing Agreements | — | — | — | $5,367,000 | $11,795,000 | $1,396,000 | $807,000 | $12,504,000 |
| Sales of Branded Pharmaceutical Products | — | — | $105,250,000 | $64,578,000 | $72,565,000 | $47,960,000 | $63,767,000 | $60,554,000 |
| Sales of Contract Manufactured Products | — | — | — | $16,106,000 | $10,042,000 | $9,221,000 | $11,139,000 | $9,119,000 |
| Sales of Rare Disease Pharmaceutical Products | — | — | $112,117,000 | $41,686,000 | $0 | — | — | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Generics and Other | $154,988,000 | $116,024,000 | $105,927,000 | $85,475,000 |
| Rare Disease and Brands | $141,240,000 | $72,469,000 | $89,173,000 | $10,538,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Rare Disease and Brands | 29.2% | 24.6% | 45.2% | 13% |
| Generics and Other | 38.8% | 36.3% | 36.6% | 36.3% |
Key facts
CIK
1023024
CUSIP
00182C103
13F (30d)
43 filings
40 filers
Visit website
Investor relations